Beneficial Effect of Oral Sildenafil Therapy on Childhood Pulmonary Arterial Hypertension

Abstract

Oral sildenafil has the potential to improve hemodynamics and exercise capacity for up to 12 months in children with PAH. Confirmation of these results in a randomized, controlled trial is essential.